BioSpace News Archive

Luciole Medical AG, a Swiss medical technology company, and Hôpital Fondation Adolphe de Rothschild announce a collaboration in brain metabolism monitoring research.

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

A new pre-print runs a head-to-head comparison between Loop Genomics, PacBio and Oxford Nanopore’s accuracy in long read microbiome sequencing.

Innate Pharma SA announced the publication of a Nature paper entitled, “Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis,” authored by Innate researchers in partnership with scientists from Hôpitaux Universitaires de Marseille AP-HM, Laveran Hospital, Aix Marseille University, the Centre d’Immunologie de Marseille-Luminy and Marseille Immunopole/AP-HM immunoprofiling laboratory at La Timone Hospital.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020.

INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP). RRP is a rare disease caused by human papillomavirus (HPV) types 6 and 11 infec

Confirms stimulation of human-HLA-restricted transgenic mouse T-cells against immunodominant epitopes of SARS-CoV-2 Spike protein

Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Dr. Roberto Iacone has been named Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005046/en/ CEO of Alentis Therapeutics, Dr. Roberto Iacone. Copyright Alentis Therapeutics Dr. Iacone is a physician

Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time. Conference Call Details Wednesday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacifi